share_log

Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Goldman Jonathan

Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities

Avalo Therapeutics | 3：首次持股聲明
SEC announcement ·  04/03 16:10
Moomoo AI 已提取核心訊息
Jonathan Goldman, a director and 10% owner of Avalo Therapeutics, Inc. [AVTX], filed an Initial Statement of Beneficial Ownership of Securities with the SEC on March 27, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that no securities are beneficially owned by Goldman. The form was signed by Donald R. Reynolds by power of attorney on April 3, 2024. This filing is a standard procedure for directors and significant shareholders, providing transparency about their holdings in the company.
Jonathan Goldman, a director and 10% owner of Avalo Therapeutics, Inc. [AVTX], filed an Initial Statement of Beneficial Ownership of Securities with the SEC on March 27, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that no securities are beneficially owned by Goldman. The form was signed by Donald R. Reynolds by power of attorney on April 3, 2024. This filing is a standard procedure for directors and significant shareholders, providing transparency about their holdings in the company.
Avalo Therapeutics, Inc. [AVTX] 的董事兼10％所有者喬納森·戈德曼於2024年3月27日向美國證券交易委員會提交了初步的證券實益擁有權聲明。表格3申報是1934年《證券交易法》第16（a）條的要求，表明高盛沒有實益擁有任何證券。該表格由唐納德·雷諾茲於2024年4月3日通過委託書簽署。該申報是董事和大股東的標準程序，爲他們在公司的持股提供了透明度。
Avalo Therapeutics, Inc. [AVTX] 的董事兼10％所有者喬納森·戈德曼於2024年3月27日向美國證券交易委員會提交了初步的證券實益擁有權聲明。表格3申報是1934年《證券交易法》第16（a）條的要求，表明高盛沒有實益擁有任何證券。該表格由唐納德·雷諾茲於2024年4月3日通過委託書簽署。該申報是董事和大股東的標準程序，爲他們在公司的持股提供了透明度。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息